Please ensure Javascript is enabled for purposes of website accessibility

Invitae Stock Falls Again in Broader Market Downturn

By Maxx Chatsko - Mar 12, 2020 at 2:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a rough few weeks for shareholders, but portfolio returns aren't measured in weeks.

What happened

Shares of Invitae (NVTA 9.25%) fell as much as 22% today after tumbling by double digits yesterday. The genetic testing company announced three acquisitions yesterday that will be funded with a combination of cash and stock, but the combined transactions total $195 million. By contrast, Invitae has lost roughly $500 million in market valuation in the last two days. 

Given the relatively small amount of dilution for the $1.3 billion company, it's clear that much of the stock's decline has much more to do with the broader market downturn. Nearly every stock is in negative territory as investors brace for the economic impact of the coronavirus pandemic. 

As of 3:08 p.m. EDT, the growth stock had settled to a 21.1% loss.

A finger pointing at a declining stock chart on a screen.

Image source: Getty Images.

So what

Invitae announced three acquisitions this week. The first was of Diploid, a company developing an artificial intelligence platform that might allow clinicians to make diagnoses from whole genome sequencing data in "minutes", according to the press release. The total transaction cost was $95 million, including $32 million in cash and $63 million in Invitae stock. 

The second and third acquisitions were of YouScript and Genelex, respectively. Both will allow Invitae to integrate pharmacogenetic information into its genetic testing platform. Such data combines an individual's genetic information with known reactions to drugs, which could potentially lead to improved dosing recommendations and fewer side effects for patients. 

Now what

It takes months of work behind the scenes to complete an acquisition. Invitae just so happened to wrap up discussions and publicly disclose them during one of the worst trading days in recent memory. But the acquisitions serve as a reminder that the business is focused on the long term. Individual investors looking for the best outcomes for their portfolio would be well served to do the same.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invitae Stock Quote
$3.07 (9.25%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.